Updated on 31 July 2013
In Taiwan, BDSI has licensed the commercialization rights to TTY Biopharm, where the product will be marketed under the brand name Painkyl
Singapore: BioDelivery Sciences International (BDSI) received regulatory approval for Onsolis in Taiwan for the management of breakthrough cancer pain in opioid tolerant, adult patients.
In Taiwan, BDSI has licensed the commercialization rights to TTY Biopharm, where the product will be marketed under the brand name Painkyl. TTY will be responsible for the cost of future product commercialization in Taiwan and expects to launch Painkyl following receipt of reimbursement pricing from the Taiwanese national healthcare system.
The approval in Taiwan results in a milestone payment of $300,000 to BDSI. Upon launch, BDSI will receive a royalty on net sales.
Dr Andrew Finn, executive vice president, product development, BDSI, said that, "We offer our thanks and congratulations to our partner TTY on the regulatory approval for this product, which will be the first drug available in Taiwan for the treatment of breakthrough cancer pain."
Onsolis is approved in the US and Canada for the treatment of breakthrough pain in opioid-tolerant adult patients with cancer and marketed in the EU as Breakyl. The commercialization rights are licensed to Meda for all territories world-wide with the exception of Taiwan and South Korea. In South Korea, the product is licensed to Kunwha Pharmaceutical.